surovatamig + acalabrutinib

**surovatamig + acalabrutinib** is a combination therapy consisting of surovatamig and acalabrutinib. - *Acalabrutinib* is a selective small molecule inhibitor of Bruton tyrosine kinase (BTK), used primarily for the treatment of B-cell malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)[1][2][3][4]. Its mechanism is irreversible inhibition of BTK, blocking B-cell receptor signaling and reducing proliferation and survival of malignant B-cells. - *Surovatamig* is not currently referenced in authoritative sources or clinical trial databases, and its precise mechanism, indication, developer, and status are unconfirmed in the provided and public resources. If surovatamig is an emerging or investigational agent, its therapeutic class and mechanism of action are unknown. The combination would theoretically represent a targeted therapy approach for hematological malignancy, in particular CLL or MCL, but surovatamig’s specifics cannot be determined.